Trial · NCT01986933
Results by group164
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 164
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12 | Placebo (Part A) | -20.07 | 95% Confidence Interval -29.94 to -10.21 | percentage change | |
| Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12 | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | -41.46 | 95% Confidence Interval -51.21 to -31.71 | percentage change | |
| Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12 | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | -61.24 | 95% Confidence Interval -71.13 to -51.35 | percentage change | |
| Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12 | Nemoliozumab (2.0 mg/kg) Q4W (Part A) | -60.46 | 95% Confidence Interval -69.98 to -50.95 | percentage change | |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) | Placebo (Part A) | Week 4 | -12.12 | Standard Deviation 40.00 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Week 4 | -26.89 | Standard Deviation 44.48 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Week 4 | -35.70 | Standard Deviation 44.29 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) | Week 4 | -33.86 | Standard Deviation 34.14 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) | Placebo (Part A) | Week 8 | -21.82 | Standard Deviation 47.00 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Week 8 | -25.17 | Standard Deviation 51.79 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Week 8 | -46.20 | Standard Deviation 42.62 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) | Week 8 | -39.89 | Standard Deviation 34.43 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) | Placebo (Part A) | Week 12 | -20.89 | Standard Deviation 47.63 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Week 12 | -27.88 | Standard Deviation 50.50 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Week 12 | -44.57 | Standard Deviation 48.21 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) | Week 12 | -40.29 | Standard Deviation 37.70 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population) | Nemoliozumab (0.1 mg/kg) Q4W (Part A + Part B) | Week 4 | -25.47 | Standard Deviation 42.41 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population) | Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B) | Week 4 | -32.11 | Standard Deviation 43.70 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population) | Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B) | Week 4 | -32.48 | Standard Deviation 34.02 | percentage change from baseline |
| Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population) | Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B) | Week 4 | -25.43 | Standard Deviation 35.58 | percentage change from baseline |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01986933/results